REFERENCES
- Lindner A, Charra B, Sherrard DJ, Schribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Eng J Med 1974; 290: 697–701, [CSA]
- Foley R, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(suppl.)S112–119, [INFOTRIEVE], [CSA]
- Locatelli F, Canaud B, Eckardt K, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272–1280, [INFOTRIEVE], [CROSSREF], [CSA]
- Stenvinkel P, Alverstand A. Inflammation in end stage renal disease: sources, consequences and therapy. Semin Dial 2002; 15(5)329–337, [INFOTRIEVE], [CROSSREF], [CSA]
- Himmelfarb J, Stenvinkel P. İkizler TA, Hakım RM. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524–1538, [INFOTRIEVE], [CROSSREF], [CSA]
- Descamps-Latscha B, Drüeke T, Witko-Sarsat V. Dialysis induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial 2001; 14: 193–199, [INFOTRIEVE], [CROSSREF], [CSA]
- Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: Which is the chicken and which is the egg?. Semin Dial 2004; 17(6)449–454, [INFOTRIEVE], [CROSSREF], [CSA]
- Gordon CA, Himmelfarb J. Antioxidant therapy in uremia: evidence-based medicine?. Semin Dial 2004; 17: 327–332, [INFOTRIEVE], [CROSSREF], [CSA]
- Wang L, Brown RJ, Varki A, Esko DJ. Heparin's anti-inflammatory effects require glucoseamine 6-0-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110(1)127–136, [INFOTRIEVE], [CROSSREF], [CSA]
- Sela S, Shurtz-Swırskı R, Shapıro G, Nasser L, Hamzı M, Shasha S, Kristal B. Oxidative stress during hemodialysis: effect of heparin. Kidney Int 2001; 39(suppl. 78)159–163, [CROSSREF], [CSA]
- Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Acta 1978; 90: 37–43, [INFOTRIEVE], [CROSSREF], [CSA]
- Sun Y, Oberley LW, Ying L. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497–500, [INFOTRIEVE], [CSA]
- Stenvinkel P. Inflammation in end-stage renal failure: could it be treated?. Nephrol Dial Transplant 2002; 17(suppl. 8)33–38, [INFOTRIEVE], [CROSSREF], [CSA]
- Bergström J, Heimbürger O, Lindholm B, Qureshi AR. Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients. J Am Soc Nephrol 1995; 6: 573, [CSA]
- Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in hemodialysis patients. Nephrol Dial Transplant 2002; 17(suppl. 8)29–32, [INFOTRIEVE], [CROSSREF], [CSA]
- Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?. Kidney Int 2001; 59(2)407–414, [INFOTRIEVE], [CROSSREF], [CSA]
- Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000; 102: 2636–2642, [INFOTRIEVE], [CSA]
- Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?. Atherosclerosis 2000; 148: 209–214, [INFOTRIEVE], [CROSSREF], [CSA]
- Hojo Y, Ikeda U, Takahashi M, Shimada K. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis 2002; 161: 403–408, [INFOTRIEVE], [CROSSREF], [CSA]
- Tsirpanlis G, Chatzipanagiotou S, Nicolaou C. Microinflammation versus inflammation in chronic renal failure patients. Kidney Int 2004; 66: 2093–2094, [INFOTRIEVE], [CROSSREF], [CSA]
- Boaz M, Mataz Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078–1083, [INFOTRIEVE], [CROSSREF], [CSA]
- Gritters M, Grooteman MP C, Schoorl M, et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153–159, [INFOTRIEVE], [CROSSREF], [CSA]
- Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 2006; 91(2)207–214, [INFOTRIEVE], [CSA]
- Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335–340, [INFOTRIEVE], [CROSSREF], [CSA]
- Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 51: 1960–1966, [CROSSREF], [CSA]
- Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002; 58: 190–197, [INFOTRIEVE], [CSA]
- Belch JJ, Chopra M, Hutchison S, Lorimer R, Sturrock RD, Forbes CD, Smith WE. Free radical pathology in chronic arterial disease. Free Radic Biol Med 1989; 6: 375–378, [INFOTRIEVE], [CROSSREF], [CSA]
- Prasad K, Gupta JB, Kalra J, Lee P, Mantha SV, Bharadwaj B. Oxidative stress as a mechanism of cardiac failure in chronic volume overload in canine model. J Mol Cell Cardiol 1996; 28: 375–385, [INFOTRIEVE], [CROSSREF], [CSA]